Facebook
X
LinkedIn
ForwardPharmacological Treatment of Depression and Anxiety with Focus on SSRIs
Funded by the Wisconsin Department of Health Services, Wis.Stat.20.435 and 51.442 and in part from the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of a 5-year cooperative agreement.
This series of online modules provides education about psychiatric diagnoses and treatment, with an educational emphasis on psychopharmacology, to Primary Care Clinicians. Given the shortage of Child Psychiatrists nationally and in Wisconsin, in particular, Primary Care Clinicians are being tasked increasingly with assessing and treating children with mental health issues. Primary Care Clinicians report having had insufficient education about psychiatric diagnoses and treatment during their residency training, but they increasingly are asked to perform mental health assessments and to provide treatment for their patients. The goal is to provide education about psychiatric assessment and treatment to Primary Care Clinicians, thereby supporting them in their role as front-line providers of mental health care to children.
Target Audience
- Primary Care Clinicians
- Allied Health Care Professionals
Learning Objectives
Participants who engage in this educational intervention will be able to:
- List the types of depression and anxiety that may benefit from SSRI treatment
- List the first steps in treatment for depression and anxiety
- Dose, titrate, monitor, and list follow-up treatment for SSRIs as a treatment for depression and anxiety
- Identify when to refer to psychiatry
- Discuss medications such as Fluoxetine, Sertraline, Citalopram, Escitalopram, Paroxetine, Bupropion, Venlafaxine, Mirtazapine, Duloxetine, Trazodone
Activity Director:
Rosa Kim, MD
Planning Committee:
- Gabriella Hangiandreou, MD
- Matthew Jandrisevits, PhD
- Colleen Manak, MD
- Nisha Shah, MD
- Martha Karlstad, MD
In accordance with the ACCME® Standards for Integrity and Independence in Accredited Continuing Education, Standard 3, all persons in control of content must disclose any relevant financial relationships. It is the policy of the Medical College of Wisconsin to identify, mitigate and disclose the absence or presence of all relevant financial relationships with ineligible companies held by the speakers/presenters, authors, planners, and other persons who may influence content of this accredited continuing education. The following in control of content had no relevant financial relationships to disclose.
- Gabriella Hangiandreou, MD
- Matthew Jandrisevits, PhD
- Colleen Manak, MD
- Nisha Shah, MD
- Martha Karlstad, MD
- Rosa Kim, MD
The following persons in control of content disclosed the following financial relationships which were reviewed via the MCW conflict of interest mitigation process and addressed:
Name | Company | Role |
Matthew David Jandrisevits | Merck & Co., Inc. | Stock (publicly traded) |
ACCME Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical College of Wisconsin and Wisconsin Child Psychiatry Consultation Program (WI CPCP). The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1 hour of participation for continuing education for allied health professionals.
Nurse Practitioner Accreditation Statement:
Medical College of Wisconsin, Inc. is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners: AANP Provider Number 150930. This program has been approved for 1 contact hour of continuing education (which includes 1 hour of pharmacology).
Physician Associate Accreditation Statement:
This activity has been reviewed by the American Academy of Physician Associates Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 14 AAPA Category 1 CME credits. Approval is valid from 1/9/2026 to 1/8/2027. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-2015009.
Available Credit
- 1.00 AAFPAAFP credit.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.
- 1.00 NP PharmacologyNP Pharmacology credit.
- 1.00 NP Contact Hours
- 1.00 PAPA credit.